Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

Next Previous
Trial Profile

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Capecitabine (Primary) ; Depoxythilone (Primary) ; Trastuzumab (Primary) ; Gemcitabine; Paclitaxel; Vinorelbine
  • Indications Advanced breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Acronyms IUI

Most Recent Events

  • 06 Jun 2023 Status changed to completed, as per results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 06 Jun 2023 Final results assessing the efficacy and safety of inetetamab plus camrelizumab and utidelone in patients with HER2-positive metastatic breast cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 15 Jul 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top